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Introduction
Leading health care centers across the country now recognize 
the paramount importance and utility of establishing a clinical 
data warehouse. In fact, some of the earliest pioneering projects 
have already crossed the 20-year mark.1–5 Primary benefits that 
have been realized as a result of these early efforts include cost 
containment and tracking patient outcomes, providing clinical 
decision support at point of care, improving prognostic accu-
racy, and facilitating research and clinical trials.6–8
Despite many positive reports from academic and clinical 
sites across the country regarding the development of data 
management and analytical tools, most centers report that the 
specific solutions that were implemented have notable limita-
tions and flaws.9The most often cited challenges are related to 
the intrinsic complexity of the underlying biomedical and clin-
ical data—the fact that information exists in both structured 
and unstructured formats, and the wide range of data owner-
ship and regulatory issues associated with collecting and organ-
izing the data.9 To address these issues, many clinical data 
warehouse projects required large up-front costs on Information 
Technology (IT) implementation, which relied, chiefly, on 
manual data entry. Once the data were migrated into the ware-
house, there was often only limited support for performing ad 
hoc queries and only minimal bioinformatics and computa-
tional tools available to enable investigators and physicians to 
systematically mine and interrogate complex genomic signa-
tures, or to detect and track subtle changes in patient response 
to therapy and treatment.
As part of our mission as a National Cancer Institute–
designated Comprehensive Cancer Center, Rutgers Cancer 
Institute of New Jersey has made the goal of implementing a 
clinical data warehouse a high priority to facilitate improve-
ments in prevention, detection, treatment, and care of cancer 
patients. Working shoulder-to-shoulder, a team of physicians, 
systems biologists, engineers, and scientists at our Center have 
designed, developed, and implemented the methods, protocols, 
and workflows to facilitate the extraction, standardization, and 
ongoing population of a Clinical Data Warehouse (Warehouse 
in subsequent text) with information originating from a full 
range of data sources, including not only the Electronic Medical 
Record (EMR) system which contains patient visit records, 
clinical history, physician order entries, and data originating 
from laboratory results, radiology reports, and pathology reports 
but also genomic sequencing studies and research-generated 
data records. Our overarching efforts focus on identifying and 
consolidating information most crucial to diagnosis, choices in 
treatment and therapy planning, as well as investigative research.
One of the great challenges when establishing a compre-
hensive Warehouse lies in the fact that a vast amount 
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of clinical data are found in unstructured or semistructured 
format. Some of these reports are generated from outside 
consultations or referring laboratories. At many institutions, 
such documents are simply scanned into images or PDF and 
attached to the patient record. Others may arrive via struc-
tured vehicles such as HL7 format, while the clinical content 
of the message is lumped into a continuous ASCII (American 
Standard Code for Information Interchange) string. These 
solutions only satisfy rudimentary requirements of founda-
tional interoperability by allowing the information to flow into 
another Healthcare Information Technology (HIT) system; 
however, the data cannot be easily interpreted in the destina-
tion database. To effectively incorporate this information into 
the Warehouse and achieve semantic interoperability,10,11 our 
team has contracted with Extract Systems (Madison, WI), a 
Wisconsin-based high-tech company, to develop and opti-
mize software that semiautomatically extracts data that would 
otherwise remain locked in paper-based documents, so that 
the information can be reliably uploaded into discrete fields 
for integration with clinical data warehouse repository. Using 
this technology, our team is able to automatically capture 
more than 500 data elements, which had previously been 
trapped in pathology reports and historic gene sequencing 
reports. Even without human supervision, the software is 
able to extract, at an accuracy rate of 96.65%, not only the 
traditional pathological description of gross and micro-
scopic pathologic findings in tumor specimen but also a full 
set of discrete elements as defined in individual cancer syn-
optic protocols from the College of American Pathologists,12 
including the most critical pathology staging information, 
which is often missing from the EMR.
Whole exome sequencing and targeted exon sequencing 
have become the methods of choice for identifying action-
able molecular traits of a given tumor. The capacity of a 
clinical data warehouse to support systematic queries facili-
tates the process of identifying candidates for new therapies 
and providing directions for future research. In this article, 
we demonstrate an automated work flow for incorporating 
sequencing results from both structured and unstructured 
sources.
During the course of this project our team has established 
productive collaborations with several vendors, which has led 
to the development of software that allows integration of radi-
ology imaging studies and digitized pathology specimens 
within the Warehouse. The colocalization of correlated data 
elements, which represent the full spectrum of clinical infor-
mation, imaging studies, and genomic information, coupled 
with our experience and expertise in advanced pattern recogni-
tion, high-performance computing, and data mining, has 
placed our team in an excellent position to optimize personal-
ized treatment, refine best practices, and provide objective, 
reproducible insight as to the underlying mechanisms of dis-
ease onset and progression.
Methods
Governance
To support the planning and development of the Warehouse, 
a Data Governance Council has been established to provide 
clinical insight and guide the methods used for gathering, 
accessing, and sharing the data. The Council is led by a cross-
section of physicians, scientists, administrators, and bioinfor-
matics and IT staff members who work in concert in the 
planning, review, and decision-making activities of the Cancer 
Center. The overarching mission of the Data Governance 
Council is to provide policy and oversight for all key, data-
centric, clinical, and research projects at Rutgers Cancer 
Institute of New Jersey. The Council is charged with estab-
lishing, reviewing, and optimizing all standing policies and 
standard operating procedures for evaluating requests from 
investigators for access and use of both de-identified and 
Protected Health Information (PHI) data sets.
As part of its charge, the Council is responsible for (1) 
providing support and training to the Rutgers Cancer com-
munity through a series of programs and workshops to sup-
port data literacy, (2) establishing a review process for 
evaluating investigator-initiated project proposals, (3) review-
ing and providing storage infrastructure and security, (4) 
advocating for data quality and ease of access, (5) addressing 
data life cycle policy issues, (6) establishing standards for 
master reference data, and (7) staying abreast of the scientific, 
technological, legal, and ethical standards and guidelines 
related to data use and disclosure that form the basis of the 
Rutgers Cancer Institute of New Jersey policies and opera-
tional decisions in addition to State, Federal, and Institutional 
Review Board (IRB) protocols.
Design and components
Figure 1 shows a high-level diagram which depicts the general 
work flow of the clinical data warehouse solution including: 
operational databases and external data sources, Extraction 
Transformation Loading (ETL) interfaces, data warehouse, 
data mart, and data analysis as shown in Figure 1A. Although 
the traditional approach for building such a system would 
begin with extracting data from the operational databases and 
external sources and then implementing an ETL to populate 
the warehouse, our team recognized the large number of failed 
attempts at other institutions to construct a functional system 
in this manner. Although the specific details may vary, the pri-
mary design flaw of many of those projects was that the pri-
mary focus was on the extraction of information from the data 
sources, before clearly identifying the use-case scenarios and 
clarifying the required data mapping. Being aware of the 
potential pitfalls of this approach, our team decided to imple-
ment a “backward-in” strategy for our project.
The key feature of the “backward-in” strategy is to first estab-
lish a remotely hosted data mart which is then manually 
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populated with data elements corresponding to a representative 
set of cases. As part of a pilot study, our staff entered approxi-
mately 1000 such cases and then began to exercise the query, visu-
alization, and logical tools featured by each candidate data mart. 
A steering committee composed of surgical and medical oncolo-
gists worked closely with our biomedical informatics team and 
IT staff to determine whether the candidate data mart provided 
adequate support for the types of experiments and investigations 
which are underway. During the same time, the Committee made 
recommendations as to whether additional data modalities or ele-
ments should be included in the repository.
Once the Committee was satisfied with the data mart and 
the data elements that it housed, our development team turned 
attention toward building a fully automatic ETL. Having con-
ducted the “backward-in” pilot study and having a solid under-
standing of how the data elements in the mart should be 
organized, the team knew exactly which data sources, mapping 
strategies, and interfaces would be required. The project then 
proceeded by completing the build and then taking advantage 
of the automated features of the ETL to allow prospective pop-
ulation of the clinical data warehouse and mart going forward.
Feeder databases and data lake
Development of a research-centric clinical data warehouse 
must offer the flexibility of accommodating new projects and 
protocols, which invariably presents new data requirements.
The industrial solution for such challenges has been to 
establish a Hadoop-based data lake,13 which can serve as a file 
reservoir to house both structured and unstructured data that 
have not yet been integrated into the warehouse schema. The 
data lake implementation uses a “schema-on-read” principle, 
which enables and requires data specialists and data scientists 
to process raw data on demand to satisfy analysis needs. As 
many of our clinical data warehouse end users are typically 
researchers and clinicians with limited IT experience, it was of 
vital importance for us to establish simple methods for manag-
ing data requirements and our staff ’s efforts. We accomplished 
this by establishing feeder databases.
Feeder databases are efforts led by research scientists to 
establish prototypical relational databases of specific subject 
areas that can subsequently be forwarded to data marts for 
integration. Our current feeder databases include data ele-
ments derived from complete synoptic pathology reports as 
well as complete itemized variant report data from exon 
sequencing studies, whereas the Warehouse focuses on more 
refined and common data elements that apply to a wider num-
ber of projects and disease groups.
Moving data directly from feeder databases to data marts 
guarantees that the corresponding data tables have the same 
level of security as all the data in the Warehouse. More impor-
tantly, these data marts provide the opportunity for end users to 
consume and evaluate data from subspecialty areas ahead of 
Warehouse development, allowing feedback to the develop-
ment team to facilitate the optimized design and ETL of the 
warehouse. The feeder databases allow continued execution of 
the “backward-in” strategy during ongoing development of the 
Warehouse.
Data mart and security
Among the software solutions offered by the company 
BioFortis, Inc. (Columbia, MD), is Labmatrix, which gained 
early adoption and recognition among prestigious institutions 
such as the National Human Genome Research Institute and 
the National Cancer Institute, and has since become a leading 
provider of information management solutions for the trans-
lational life science research community. The Qiagram soft-
ware module supplements these capabilities with intuitive, 
user-friendly graphical query–building capabilities. We 
Figure 1. Architecture of the clinical data warehouse project. (A) Key layers of the data warehouse layout. (B) Components in the implementation. The 
data lake component as well as further reporting and mining tools have not yet been implemented and are therefore rendered in gray.
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adopted a combination of these software models as our data 
mart solution, which established a unique, secure, and scalable 
scientific intelligent environment that enables our researchers 
to aggregate, explore, and interrogate information as it is col-
lected. The BioFortis solution was designed to be subject-cen-
tric and has strong built-in capability to selectively display 
identified or de-identified query results to users according to 
their access privileges to specific IRB-approved research pro-
tocols. Users can either manipulate specific prebuilt reports for 
their desired output or work with honest brokers to build 
complicated ad hoc output of results. The graphical presenta-
tions of the queries clearly represent their logical formation 
and are exceptional tools which foster brainstorming among 
scientific and technical members of the team.
As approved by the IRB committee at Rutgers Cancer 
Institute of New Jersey, the precision medicine honest broker 
system14 is in place to help researchers use the infrastructure 
provided by the Warehouse (Rutgers Cancer Institute of New 
Jersey IRB protocols 0220100249, 2012002075, 0220090048, 
and 0220044862). The Data Governance Council has desig-
nated Honest Broker Administrators to review all data requests 
and associated IRB protocols prior to undertaking any new 
study. The retrieval can either exclude all patient identifying 
information or include limited data PHI elements as specified 
by the study IRB. Delivery of the information can be arranged 
in combination of several forms, including (1) 1-time data 
download, (2) limited-access data mart browsing capability 
including allowed data elements, (3) limited-time hypothesis-
generating query capability over specified data points, and (4) 
live, online reports that can be filtered and aggregated by user.
Extracting discrete data from unstructured and 
paper forms
The necessity to integrate data originating from disparate EMR 
systems often makes it useful to store text or scanned paper 
reports in their entirety for subsequent access by the physicians 
and other clinical personnel. Although comprehensible by 
human readers, patients’ medical information embedded in these 
reports is not easily integrated into clinical databases, without 
enlisting advanced optical character recognition and text-based 
analytical technologies. Our team partnered with Extract 
Systems to implement the software and systems to automate the 
process of detecting and extracting unstructured clinical infor-
mation that was embedded in paper or text documents such as 
pathology reports and genomic sequencing reports.
Synoptic cancer reporting12,15,16 and pathology staging17 are 
critical for producing accurate and complete cancer pathology 
reporting and supporting collaboration among clinicians for the 
optimal management of cancer patients. Although synoptic 
reporting has already been implemented in most Laboratory 
Information Systems (LIS), the EMR typically receives a full text 
report via version 2 HL7 protocol.18–20 By developing a set of 
universal rules based on CAP’s synoptic protocol with 
implementation details provided by the Department of Pathology 
and Laboratory Medicine, Robert Wood Johnson University 
Hospital, the approach that we implemented is able to reliably 
process the entire ensemble of information of each pathology 
report into discrete data elements and output them in a corre-
sponding structured XML format that subsequently transformed 
into compatible data structure for the data warehouse. The 
Warehouse is therefore capable of supporting queries into every 
synoptic data element of the reports including but not limited to 
margin details, lymph node findings, and additional pathological 
findings. To date, our team has implemented rules for processing 
synoptic reports of breast, prostate, melanoma, colon, rectum, 
neuroendocrine tumor, and pancreas exocrine and pancreas endo-
crine tumors and plans to incorporate other tumor forms in near 
future. The rules can also be easily adapted to any future changes 
into the synoptic reporting scheme and be fully compatible with 
implementations in other hospitals and LIS systems.
Although genomic sequencing entities such as Foundation 
Medicine (Cambridge, MA) are capable of reporting in XML 
formats, many users still receive emailed or faxed reports from 
referring physicians and patients in PDF. The Extract Systems 
implementation is also proficient in extracting genomic altera-
tions, significant negative mutations, and variants of unknown 
significance (VUS) from these reports into discrete form and 
allows cataloging of the information into databases.
Image archive
One of the data types most often overlooked when building a 
clinical data warehouse are medical images,21 which play a 
key role in cancer diagnosis and prognosis. As medical imag-
ing data are heterogeneous and large, they take additional 
architectural layout, multiple software interfaces, and careful 
security planning to allow users to retrieve and display of this 
visual information.
Pathology specimens relevant to the precision medicine pro-
ject as well as a range of other research protocols were imaged 
at the Imaging Shared Resource at Rutgers Cancer Institute 
of New Jersey. An Olympus VS120 scanner (Olympus 
Corporation, Center Valley, PA) is capable of digitizing slides 
with maximum magnification of 40× and throughput of 100 
slides per load. The resulted images were transferred to an 
online database. Each whole slide image in itself does not con-
tain patient identifier, and they require privileged information 
to be linked to research protocol and patient record. For exam-
ple, pathology images were linked through pathology data types 
in the schema. Users can simply click on a URL from the data 
mart at which point a Web viewer interface provides access to 
the corresponding whole slide images for that case. The inter-
face supports visualization and navigation about the imaged 
specimen. Radiology images were previously transmitted from 
the Picture Archiving and Communication Systems (PACS) 
located in the Department of Radiology at Robert Wood 
Johnson University Hospital using standard transfer protocols.
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Each image record referenced in the clinical data warehouse 
is linked to the actual imaging data using URL into a Web 
image archive application, which supports user viewing and 
manipulation. The Web image archive applications supporting 
this access satisfy the following requirements:
1. The application should support proper visualization of 
the images via a Web browser. There are different 
requirements for displaying each type of medical images. 
Efficient traversing of whole slide images requires pan-
ning and zooming. Stack support is essential for brows-
ing computed tomographic images.
2. Each image can be accessed via a direct URL. The appli-
cation does not require user to search for a patient or 
time stamp to reach the desired image.
3. The URLs can be automatically retrieved from the appli-
cation’s back-end database into the clinical database with 
complementary image metadata.
4. Image access is restricted based on user account and 
password. Therefore, if an URL is copied and sent to 
another physician, the recipient still needs his or her own 
proper privilege for access.
5. The application server is strategically configured for net-
work security at the institution.
6. If some users do not have access to PHI, the image 
access is also stripped of protected information. This 
may demand PHI-free version of images to be served 
and/or a separate, PHI-free image server configuration 
to be established.
Document archive
The data warehouse ETL process closely integrates with the 
extraction workflows of unstructured information and tracks 
the storage of the source data files. The Warehouse maintains a 
reservoir of copies to the original pathologic report or genomic 
sequencing report so that user have the capability to easily call 
back, interrogate, and even reprocess these unstructured data, 
should more advanced processing algorithms are developed to 
understand such data. Similar to the images, these links can be 
invoked interactively through the BioFortis data mart, and 
through downstream applications.
Targeted exon sequencing
Rutgers Cancer Institute of New Jersey has arranged with 
Foundation Medicine and RUCDR Infinite Biologics 
(Piscataway, NJ) to receive a full complement of discrete data 
elements for targeted exon sequencing studies performed at 
their facilities. Annotated clinical summary reports in PDF as 
well as the corresponding data-rich XML reports are trans-
ferred, regularly, from these services through secure network 
connections and, with help of well-defined structure schema 
files, are extracted, transformed, and loaded into a prototype 
feeder database of the Warehouse with an interface developed 
using Informatica (Redwood City, CA) software. The result-
ing feeder database includes the variants with clinical signifi-
cance, VUS, copy number gains and losses, gene rearrangement 
- all with clinical annotation as well as details on sequencing 
depth, allele frequency and sample purity measures. Gene 
names in the variants data set were mapped to latest Human 
Genome Organization (HUGO) gene names and indexes 
published by the HUGO Gene Nomenclature Committee 
(HGNC) (http://genenames.org).
A separately maintained data server is used to store exome 
sequencing data files transmitted from the sequencing services. 
The Warehouse maintains links to these files so that research-
ers, with proper permission, can access the server, directly, to 
retrieve these files in spite of their large size.
Results
The oncology clinical data warehouse project was built under 
the overall umbrella of the precision medicine initiative at the 
Rutgers Cancer Institute of New Jersey; therefore, the key use 
cases presented in this article are tightly tied to providing data 
support and propelling advances in clinical applications and 
investigative oncology research. The Molecular Tumor Board, 
among other programs under the initiative, as well as the 
Oncology Research Information Exchange Network (ORIEN) 
project provided much of the motivation that inspired and 
benchmarked our progress.
Institutional Molecular Tumor Board
The precision medicine programs and clinical services which 
are currently underway at Rutgers Cancer Institute of New 
Jersey required the establishment of a weekly Molecular Tumor 
Board to enable physicians to discuss challenging clinical can-
cer cases for which clinical-grade tumor sequencing data have 
been obtained. Patients presented at the Tumor Board have 
had clinical-grade sequencing of their tumor specimens 
obtained either in the context of a tumor sequencing protocol 
at Rutgers Cancer Institute of New Jersey or have had tumor 
sequencing performed at as part of their routine clinical care. 
Patients with rare histology cancers or with tumor refractory to 
standard treatment are prioritized for review. The Board is 
composed of a full range of expert clinicians, including medical 
oncologists, radiation therapists, surgeons, pathologists as well 
as basic scientists, systems biologists and bioinformatics scien-
tists, clinical geneticists, representatives from our early phase 
clinical trials group, and experts in biomedical ethics.
At presentation, the sequencing data are reviewed in 
depth by a team of physician-scientists with experience in 
genomic analysis and cancer biology. The biological and 
clinical relevance of potential driver mutations are identi-
fied, and potential targeted treatment strategies are raised. A 
discussion regarding targeted therapies is held for each case, 
and a consensus reached regarding possible therapeutic 
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options. Recommendations often include referral to appro-
priate clinical trials, potential use of off-label therapies 
when clinical trials are not available, and guidance regarding 
further diagnostic interventions. A letter summarizing the 
discussion is sent to the referring clinician for each case. 
Follow-up clinical information and outcome data are gath-
ered on each case where available. The Rutgers Cancer 
Institute Tumor Board is routinely broadcast as interactive 
sessions with investigators located at collaborating 
Institutions using Health Insurance Portability and 
Accountability Act–approved procedures and protocols.22–24 
The Warehouse has been designed to allow capture of the 
clinically salient data elements generated during the course 
of this process, including but not limited to patient demo-
graphics, family history, diagnosis, treatment, pathology 
report and staging, lab tests results, as well as genomic vari-
ations generated from paneled gene sequencing, to allow 
subsequent viewing, mining, and analysis by the clinical and 
research community.
Oncology Research Information Exchange Network
As a logical extension of the Warehouse and precision medi-
cine activities which are being conducted, our institution has 
recently become a participating member of the Oncology 
Research Information Exchange Network (ORIEN). ORIEN 
is a national alliance, which was formed to enable investigators 
from leading institutions across the country to share “big data” 
for cancer research. The Network was established in 2014 by 
founding members Moffitt Cancer Center, Ohio State 
University Comprehensive Cancer Center, Arthur G. James 
Cancer Hospital, and Richard J. Solove Research Institute in 
Columbus. ORIEN members use a standardized protocol to 
follow patients throughout their lifetime (ie, Total Cancer 
Care Protocol) and share both clinical and molecular data 
from patients enrolled in the protocol to enhance discovery 
and create evidence of what is the most effective therapy for 
individual patients. In addition to the founding institutions, 
ORIEN members as of today include City of Hope Cancer 
Center, University of Virginia Cancer Center, University of 
Colorado Cancer Center, University of New Mexico Cancer 
Center, Morehouse School of Medicine, Rutgers Cancer 
Institute of New Jersey, University of Southern California 
Norris Cancer Center, and many more (http://oriencancer.
org/#members-list). Our team at Rutgers will leverage the 
data collected through ORIEN to facilitate systematic investi-
gations, which are focused on rare malignances for which any 
one institution is unable to acquire sufficient number of cases 
for rigorous statistical analysis.
The IT challenges of generating cohort patient data for the 
ORIEN project were in perfect alignment with our efforts 
directed toward developing the clinical data warehouse, with 
many of the data elements of interest overlapping, especially 
as they relate to patient diagnosis, mortality, treatment, and 
biospecimens. In this use case, information from source sys-
tems—EMR, cancer registry, biospecimen banking system, 
and molecular testing results—was integrated, de-identified, 
and transformed in accordance to the Observational Medical 
Outcomes Partnership (OMOP) data model25 so they could 
be transmitted and cataloged in the ORIEN central reservoir.
Example precision medicine use case
With the help of BioFortis technology, the data marts can host 
project-specific patient data to suit various needs of data access 
with user-based access control. Sophisticated queries can be 
built to execute complicated scientific logic and retrieve spe-
cific data sets.
Although BioFortis queries can be constructed to suit a 
wide variety of specific data requirement, user can also lever-
age on BioFortis’s reporting capability to access data without 
immediate programming help. These data reports are based 
on prebuilt queries to suit general needs of the users. The 
data reports can easily incorporate filters to help user tailor 
the retrieval list. Figure 2 depicts an example where patient 
cohort was assembled with specific gene mutation and tumor 
diagnosis and treated with therapeutic agents. Users with 
appropriate IRB clearance are able to access additional infor-
mation for a given data set, including the capacity to access 
and interrogate imaged pathology specimens. More advanced 
users can receive training to build ad hoc queries into their 
data mart or work closely with honest brokers to bring scien-
tific logic to actual data.
Tissue microarray use case
Tissue microarray (TMA) technology26,27 is a cohort research 
tool for assessing tumor morphology and protein marker 
expression. Researchers often make discoveries by correlating 
TMA results with clinical information. Although some infor-
mation was collected when each TMA was constructed, it was 
usually limited in comparison with what a comprehensive clin-
ical data warehouse could offer. Therefore, as one of the first 
use cases to exercise our clinical data warehouse, as well as the 
first requests into the honest broker system, a research prostate 
cancer TMA, which was previously constructed by our cancer 
center’s BioSpecimen Repository Service and Histopathology 
Shared Resources, with no clinical data other than diagnosis of 
record (prostate adenocarcinoma) and Gleason score, was 
revisited by the team.
Adhering to policies of the honest broker system, research-
ers obtained new IRB approvals to collect further information 
on the TMA from the Office of Human Research Services 
before submitting data collection requests to honest broker 
administrators, which clearly described the project as well as 
the clinical information that was desired. Clinical members of 
the original research protocol inspected and quality-assured a 
subset (10%) of the clinical information before the data were 
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made available in the Warehouse. The honest broker adminis-
trator mediated further communications between the user and 
the honest broker so that the honest broker can work with the 
data warehouse administrator to reidentify the patients 
included in the TMA, build specific queries into the data ware-
house, and produce data worksheets as requested. After being 
inspected by the honest broker administrator, the final data set 
released to researchers included, with reference to location on 
the TMA block, de-identified clinical information, including 
demographics (without PHI), biopsy pathology result, pros-
tatectomy pathology result, Gleason grading, pathology and 
clinical staging, patient visit information, medical treatment, 
selected pre- and postsurgical lab tests, as well as links to each 
patient’s tumor whole slide images. In addition, the honest 
broker built query to identify patients with biochemical 
recurrence defined as 1) two consecutive prostate-specific 
antigen tests after surgery with increasing result levels and 2) 
the final result being over 0.2 ng/mL.
Figure 2. Example of using BioFortis Qiagram interface to formulate and execute precision medicine queries. (A) Query building diagram using Qiagram 
(simplified for display purposes). (B) The result report can be published for general user access. The report form allows drop-down menu selection for 
close examination according to individual interests. The example shows a cohort of lung cancer patients presenting with EGFR (Epidermal Growth Factor 
Receptor) mutation who have been treated with therapeutic agents.
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Integrating pathology reports and scanned 
sequencing reports
Each pathology report enters in our EMR system in HL7 for-
mat and is subsequently incorporated into EMRs of corre-
sponding patients in textual/ASCII format. When displayed to 
EMR users, these reports show proper alignment for optimal 
human comprehension. Feeding these reports into data ware-
house, however, requires well-defined data elements to be 
properly recognized and extracted.
Our team worked closely with pathologists at Rutgers 
Robert Wood John University Hospital and data expert at 
Extract Systems to define data elements to be extracted from 
pathology reports and synoptic cancer reports. In general, sur-
gical pathology reports include a final diagnosis text, entered as 
sentences or paragraphs of free texts with lack of standardized 
vocabularies among pathologists; gross and microscopic 
description of the specimen received and final pathologic diag-
nosis on each part of submitted surgical specimen; immunohis-
tochemistry and special stains results; along with addendums 
and amendments. A surgical pathology report may also include 
1 or more synoptic reports, each correspond to 1 lesion in the 
surgical specimen. The College for American Pathologists had 
recommendations for clear and consistent reporting of tumor-
ous lesions in the synoptic reports; therefore, the set of data 
elements was well defined both medically and semantically to 
be extracted into a Warehouse, with limited free texts. One 
caveat is that these synoptic reports are consistently updated, at 
times with differences in staging between different versions. In 
many cases, pathology report included result of molecular stud-
ies, which, because it is a young and growing field, the reports 
are generally more standardized, allowing for straightforward 
extraction. The CoPath implementation (Cerner Corporation, 
Kansas City, MO) used in Robert Wood Johnson University 
Hospital closely adhered to the guidelines so that our system 
can be easily generalized to other hospitals and institutions.
In an assessment of Extract Systems implementation, a bal-
anced set of surgical pathology reports, including approxi-
mately 20 synoptic reports of each recognized type, a small set 
of reports of other synoptic forms, as well as faxed and/or 
scanned Foundation Medicine sequencing reports, was sub-
mitted for automatic data extraction based on rules established 
at the Extract Systems software. Trained personnel used the 
provided quality-control interface to examine each extracted 
data element. The quality-control interface was specifically 
designed for showing all extracted data elements in a user-
friendly electronic form, with the original report displayed side 
by side for review as shown in Figure 3. As the quality-control 
personnel hit the Tab key to traverse through each data ele-
ment in the form, the corresponding text from the original 
report, where extraction of the very element originated, was 
highlighted. If the extraction is not accurate, user can overwrite 
the element, or, more easily, use the software tool to swipe the 
correct area of the original report to re-extract the data. Text 
highlighting is most often in green color, signaling high confi-
dence of the detection. Occasionally, orange highlights appear 
when further attention is required from the human operator in 
case when the recognition and extraction may be ambiguous to 
the algorithm. We found this display of confidence interval 
highly useful to achieve efficiency and maintain operator’s 
attention during the quality-control process.
Through Extract Systems platforms’ built-in quality monitor-
ing functionality, we tracked the generation and quality-control 
process of a total of 18 530 data elements, which originated from 
26 genetic analysis reports and 212 pathology reports, including 
164 synoptic tumor forms. For performance evaluation of the 
Extract Systems algorithms, we considered the quality-controlled 
data to be accurate, and any data field that was touched up, cor-
rected, or added/deleted by human operators in the quality-con-
trol process was captured error. As a result, the overall accuracy of 
automatic data element extraction by Extract Systems platform 
was determined to be 96.65%. Of course, the actual data extrac-
tion work flow included a quality-control team that corrects any 
errors that may have been introduced during the recognition pro-
cess and ensures quality of the resulting data set.
Discussion and Conclusion
During the course of constructing, developing, and exercising 
the oncology data warehouse, 1 key challenge that was regu-
larly confronted was how to maintain a balance between keep-
ing the database concise and focused, versus providing views of 
the data that offer a comprehensive summary of the salient 
clinical information. Although the most common usage of the 
Warehouse pertains to querying to identify specific patient 
cohorts with an emphasis on positive diagnostic tests (eg, 
pathology synoptic) and summarized data (such as cancer-spe-
cific diagnoses, annotated genetic variations, and therapeutic 
outcomes), our team also contended with demands from our 
researchers to support big data mining research, which often 
required thorough and temporal assembly of patient visits, 
lab tests, low-level sequencing reads in the form of Binary 
Alignment/Map (BAM) files, or variation calling files.
Reflecting on our strategy of implementing the “backward-
in” strategy to develop the Warehouse, we recognize that it 
offered many merits, including drawing quick successes to gain 
wider support from management and clinical users, prioritiz-
ing the ETL on the most essential components of clinical data, 
as well as allowing us to lay out and exercise the Warehouse in 
parallel to the development of use-case–based applications. 
This strategy of building out the Warehouse framework based 
on key use cases, if not carefully implemented, could potentially 
lead to a limited ETL that will not support the addition of new 
use cases, and hence reduce usability of the Warehouse going 
forward. The success of this project leveraged the expert knowl-
edge and guidance provided by our Data Governance Council 
through continuous communication, regular brainstorming 
sessions, and iterative prototyping. Another unique effort to 
ensure long-term success of the Warehouse was the parallel 
Foran et al 9
development of the feeder databases to prototype and evaluate 
data types and modalities as candidate expansions to the core 
Warehouse schema. Other possible technical extensions of the 
Warehouse include expansion of the data elements collected 
and implementation of natural language processing modules to 
allow automated processing of clinical free text to incorporate 
searchable information, integration of image analysis modules 
to support generation and indexing of image-based features to 
support content-based image retrieval and computer-aided 
detection, as well as online processing and visualization tools 
for genetic data.
A clinical data warehouse is composed of many compo-
nents; most of them run on commercial software systems. 
When selecting private vendors for each component, the 
team at Rutgers Cancer Institute of New Jersey emphasized 
not only on their experience in related fields but also on the 
flexibility of their products in accommodating data and appli-
cations suitable for the Warehouse project. The vendors’ 
Figure 3. An example of pathology report data extraction using Extract Systems software. (A) After the software performs automatic data detection and 
extraction, the verification software interface displays the report-in-process on right-hand side of screen, to be compared with the extracted information on 
dynamically generated data form on the left side. Screen capture shows an example section containing part of a synoptic pathology report. Please note 
one selected data element (in green) with its highlighted counterpart on the original report for easy verification. (B) Corresponding section of the resulting 
XML output file was subsequently loaded into the Warehouse.
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cooperation provided a substantial boost to the continued 
progress of the project.
A wide range of clinical data warehouse solutions are being 
developed and evaluated at leading institutions across the 
country to support the steady rise in the number of Precision 
Medicine and Translational programs that are being estab-
lished. The success of establishing a comprehensive clinical 
data warehouse at our Institution in which we have included 
pathology, genetics, and imaging data in a relatively short time 
in Rutgers Cancer Institute of New Jersey is attributed to care-
ful planning and governance from institute executives, close 
collaboration with key clinical and operational departments, 
careful selection of software partners, as well as excellent com-
munication and orchestration from the development and 
research team. The colocalization of such a broad number of 
correlated data elements representing the full spectrum of clin-
ical information, imaging studies, and genomic information 
coupled with our experience and expertise in advanced pattern 
recognition, high-performance computing, and data mining 
has positioned our team with unique opportunities to optimize 
personalizing treatment, refining best practices, and providing 
objective, reproducible insight as to the underlying mecha-
nisms of disease onset and progression.
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